Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Botched shareholder communications and capital allocation

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 29, 2021 7:32pm

162 Views

Post# 33098648

RE:RE:Botched shareholder communications and capital allocation

Wow-- that situation can't end well. If I were her I would resign rather than be smeared that way. Given some of the sell side comments posted in that presentation that very specifically highllight the "internal confusion" of the company, I wonder if there is a "street view" of her that rubs the wrong way. Not particularly good to be associated with situations like that. FYI -- she will be on the call for us.

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute